Annals of Clinical and Experimental NeurologyAnnals of Clinical and Experimental NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-2533Eco-Vector112410.17816/ACEN.1124ReviewsОбзорыReview ArticleOptimization of laboratory diagnostics of neuromyelitis optica spectrum disorders: indications and algorithmsОптимизация лабораторной диагностики заболеваний спектра оптиконевромиелита: показания и алгоритмыhttps://orcid.org/0000-0001-7256-26686243-8805SimanivTaras O.СиманивТарас Олегович
Russian Federation

Cand. Sci. (Med.), senior researcher, 6th Neurological department, Institute of Clinical and Preventive Neurology, Research Center of Neurology

к.м.н., с.н.с. 6-го неврологического отделения Института клинической и профилактической неврологии Научного центра неврологии

simaniv@neurology.ruhttps://orcid.org/0000-0002-9769-447XKrasnovVladimir S.КрасновВладимир Сергеевич
Russian Federation

Cand. Sci. (Med.), associate professor, Department of neurology, Academician I.P. Pavlov First St. Petersburg State Medical University

к.м.н., доцент каф. неврологии Первого Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова, Санкт-Петербург

krasnov_volod@mail.ruhttps://orcid.org/0000-0002-4998-3699LapinSergey V.ЛапинСергей Владимирович
Russian Federation

Cand. Sci. (Med.), Head, Laboratory of diagnostics of autoimmune diseases; Head, Scientific and methodological center of molecular medicine, Academician I.P. Pavlov First St. Petersburg State Medical University

к.м.н., зав. лаб. диагностики аутоиммунных заболеваний, научно-методическим центром Минздрава России по молекулярной медицине Первого Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова

svlapin@mail.ruhttps://orcid.org/0000-0002-4373-4747BembeevaRaisa T.БембееваРаиса Цеденкаевна
Russian Federation

D. Sci. (Med.), Associate Professor, Professor, Department of neurology, neurosurgery and medical genetics named after academician L.O. Badalian, Faculty of pediatrics, Pirogov Russian National Research Medical University

д.м.н., доцент, профессор каф. неврологии, нейрохирургии и медицинской генетики имени академика Л.О. Бадаляна педиатрического факультета Российского национального исследовательского медицинского университета им. Н.И. Пирогова

dr.bembeeva@yandex.ruhttps://orcid.org/0000-0002-7938-3782KorobkoDenis S.КоробкоДенис Сергеевич
Russian Federation

Cand. Sci. (Med.), neurologist, Head, Center for multiple sclerosis and other autoimmune diseases of the nervous system, Novosibirsk State Regional Clinical Hospital; assistant, Department of clinical neurology and neurogeriatrics, Faculty of advanced training and professional retraining, Novosibirsk State Medical University; senior researcher, Neuroscience laboratory, International Tomography Institute of Siberian Branch of the Russian Academy of Sciences

к.м.н., врач-невролог, зав. Центром рассеянного склероза и других аутоиммунных заболеваний нервной системы Государственной Новосибирской областной клинической больницы; ассистент каф. клинической неврологии и нейрогериатрии факультета повышения квалификации и профессиональной переподготовки врачей Новосибирского государственного медицинского университета; с.н.с. лаб. нейронаук Института «Международный томографический центр»

denis.s.korobko@gmail.comhttps://orcid.org/0000-0001-6625-049XBelkoElena A.БелькоЕлена Алексеевна
Russian Federation

Head, Department of autoimmune research, clinical laboratory diagnostics doctor, clinical diagnostic laboratory "INVITRO SPb"

зав. отделом аутоиммунных исследований, врач клинической лабораторной диагностики клинико-диагностической лаборатории «ИНВИТРО СПб»

belko_lena@mail.ruhttps://orcid.org/0000-0001-9604-7775ShabalinaАlla A.ШабалинаАлла Анатольевна
Russian Federation

D. Sci. (Med.), leading researcher, Head, Laboratory of hemorheology, hemostasis and pharmacokinetics (with clinical laboratory diagnostics), Research Center of Neurology

д.м.н., в.н.с., рук. лаб. гемореологии, гемостаза и фармакокинетики (с клинической лабораторной диагностикой) Научного центра неврологии

ashabalina@yandex.ruResearch Center of NeurologyНаучный центр неврологииAcademician I.P. Pavlov First St. Petersburg State Medical UniversityПервый Санкт-Петербургский государственный медицинский университет имени академика И.П. ПавловаPirogov Russian National Research Medical UniversityРоссийский национальный исследовательский медицинский университет имени Н.И. ПироговаNovosibirsk State Regional Clinical HospitalГосударственная Новосибирская областная клиническая больницаNovosibirsk State Medical UniversityНовосибирский государственный медицинский университетInternational Tomography Institute of Siberian Branch of the Russian Academy of SciencesИнститут «Международный томографический центр» СО РАНClinical diagnostic laboratory "INVITRO SPb"Клинико-диагностическая лаборатория «ИНВИТРО СПб»0807202418284942004202422052024Copyright ©; 2024, Simaniv T.O., Krasnov V.S., Lapin S.V., Bembeeva R.T., Korobko D.S., Belko E.A., Shabalina А.A.Copyright ©; 2024, Симанив Т.О., Краснов В.С., Лапин С.В., Бембеева Р.Ц., Коробко Д.С., Белько Е.А., Шабалина А.А.2024Simaniv T.O., Krasnov V.S., Lapin S.V., Bembeeva R.T., Korobko D.S., Belko E.A., Shabalina А.A.Симанив Т.О., Краснов В.С., Лапин С.В., Бембеева Р.Ц., Коробко Д.С., Белько Е.А., Шабалина А.А.https://creativecommons.org/licenses/by/4.0https://annaly-nevrologii.com/pathID/article/view/1124

Neuromyelitis optica spectrum disorders are a group of autoimmune demyelinating diseases of the central nervous system characterized by severe exacerbations with development of residual neurological deficit. Anti-aquaporin-4 antibody is one of key factor in diagnosing, differentiating, and prescribing pathogenetic therapy. The paper discusses tests and methods of detecting anti-aquaporin-4 antibodies.

Заболевания спектра оптиконевромиелита — группа аутоиммунных демиелинизирующих заболеваний центральной нервной системы, которые характеризуются тяжёлыми обострениями с формированием остаточного неврологического дефицита. Определение антител к аквапорину-4 является одним из ключевых аспектов диагностики, дифференциальной диагностики и назначения патогенетической терапии. В статье обсуждаются показания к назначению исследования и методики определения антител к аквапорину-4.

neuromyelitis optica spectrum disorderslaboratory diagnosticsanti-aquaporin-4 antibodiesзаболевания спектра оптиконевромиелиталабораторная диагностикаантитела к аквапорину-4Nishiyama S., Seok J.M., Wright A.E. et al. Anti-aquaporin-4 immune complex stimulates complement-dependent Th17 cytokine release in neuromye- litis optica spectrum disorders. Sci. Rep. 2024;14(1):3146. DOI: 10.1038/s41598-024-53661-5Ma X., Kermode A.G., Hu X., Qiu W. NMOSD acute attack: understanding, treatment and innovative treatment prospect. J. Neuroimmunol. 2020;348:577387. DOI: 10.1016/j.jneuroim.2020.577387Palace J., Leite M.I., Nairne A., Vincent A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch. Neurol. 2010;67(8):1016–1017. DOI: 10.1001/archneurol.2010.188Ayzenberg I., Schöllhammer J., Hoepner R. et al. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. J. Neurol. 2016;263(3):575–582. DOI:10.1007/s00415-015-7991-1Yamout B.I., Beaini S., Zeineddine M.M., Akkawi N. Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder. Mult. Scler. 2017;23(9):1297–1300. DOI:10.1177/1352458517694086Azzopardi L., Cox A.L., McCarthy C.L. et al. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J. Neurol. 2016;263(1):25–29. DOI: 10.1007/s00415-015-7925-yGahlen A., Trampe A.K., Haupeltshofer S. et al. Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. Neurol. Neuroimmunol. Neuroinflamm. 2017;4(4):e363. DOI:10.1212/NXI.0000000000000363Bonnan M., Berthelot E., Cabre P. Multiple sclerosis-like NMOSD patients suffer severe worsening of status after fingolimod initiation. Mult. Scler. Relat. Disord. 2021;52:102975. DOI: 10.1016/j.msard.2021.102975Wingerchuk D.M., Banwell B., Bennett J.L. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189. DOI: 10.1212/WNL.0000000000001729Kleiter I., Traboulsee A., Palace J. et al. Long-term efficacy of satra- lizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol. Neuroimmunol. Neuroinflamm. 2022;10(1):e200071. DOI: 10.1212/NXI.0000000000200071Wingerchuk D.M., Fujihara K., Palace J. et al. Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. Ann. Neurol. 2021;89(6):1088–1098. DOI: 10.1002/ana.26049Pittock S.J., Barnett M., Bennett J.L. et al. Ravulizumab in aquaporin-4-posi- tive neuromyelitis optica spectrum disorder. Ann. Neurol. 2023;93(6):1053–1068. DOI:10.1002/ana.26626Бойко А.Н. Комментарии к статье «Консенсусное мнение по ведению пациентов с заболеваниями спектра оптиконевромиелита: вопросы терминологии и терапии». Неврология, психиатрия, психосоматика. 2023;15:119–122.Yin H.X., Wang Y.J., Liu M.G. et al. Aquaporin-4 antibody dynamics and relapse risk in seropositive neuromyelitis optica spectrum disorder treated with immunosuppressants. Ann. Neurol. 2023;93(6):1069–1081. DOI: 10.1002/ana.26623Kim W., Lee J.E., Li X.F. et al. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Mult. Scler. 2012;18(5):578–586. DOI: 10.1177/1352458511424590McCracken L., Zhang J., Greene M. et al. Improving the antibody-based evaluation of autoimmune encephalitis. Neurol. Neuroimmunol. Neuroinflamm. 2017;4(6):e404. DOI: 10.1212/NXI.0000000000000404Chan K.H., Kwan J.S., Ho P.W. et al. Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays. J. Neuroinflammation. 2010;7:50. DOI: 10.1186/1742-2094-7-50Lennon V.A., Kryzer T.J., Pittock S.J. et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 2005;202(4):473–477. DOI: 10.1084/jem.20050304Lennon V.A., Wingerchuk D.M., Kryzer T.J. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–2112. DOI: 10.1016/S0140-6736(04)17551-XJarius S., Franciotta D., Paul F. et al. Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry. J. Neurol. Sci. 2012;320(1–2):32–37. DOI: 10.1016/j.jns.2012.06.002Waters P., Reindl M., Saiz A. et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J. Neurol. Neurosurg. Psychiatry. 2016;87(9):1005–1015. DOI: 10.1136/jnnp-2015-312601Dalmau J., Graus F. Antibody-mediated encephalitis. N. Engl. J. Med. 2018;378(9):840–851. DOI: 10.1056/NEJMra1708712Kang E.S., Min J.H., Lee K.H., Kim B.J. Clinical usefulness of cell-based indirect immunofluorescence assay for the detection of aquaporin-4 antibodies in neuromyelitis optica spectrum disorder. Ann. Lab. Med. 2012;32(5):331–338. DOI: 10.3343/alm.2012.32.5.331Ruiz-García R., Muñoz-Sánchez G., Naranjo L. et al. Limitations of a commercial assay as diagnostic test of autoimmune encephalitis. Front. Immunol. 2021;12:691536. DOI: 10.3389/fimmu.2021.691536Gao F., Zhang Y., Lv J. et al. How to improve the sensitivity and specificity of cell-based assays in detecting autoantibodies in neuroimmune diseases. Ann. Transl. Med. 2023;11(7):281. DOI: 10.21037/atm-21-3072Woodhall M., Mgbachi V., Fox H. et al. Utility of live cell-based assays for autoimmune neurology diagnostics. J. Appl. Lab. Med. 2022;7(1):391–393. DOI: 10.1093/jalm/jfab133Redenbaugh V., Montalvo M., Sechi E. et al. Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. Mult. Scler. J. Exp. Transl. Clin. 2021;7(4):20552173211052656. DOI: 10.1177/20552173211052656Waters P.J., McKeon A., Leite M.I. et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78(9):665–671. DOI: 10.1212/WNL.0b013e318248dec1Majed M., Fryer J.P., McKeon A. et al. Clinical utility of testing AQP4-IgG in CSF: guidance for physicians. Neurol. Neuroimmunol. Neuroinflamm. 2016;3(3):e231. DOI: 10.1212/NXI.0000000000000231Collongues N., Marignier R., Zéphir H. et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology. 2010;74(9):736–742. DOI: 10.1212/WNL.0b013e3181d31e35Takahashi T., Fujihara K., Nakashima I. et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007;130(Pt 5):1235–1243. DOI: 10.1093/brain/awm062Ruiz-Gaviria R., Baracaldo I., Castañeda C. et al. Specificity and sensitivity of aquaporin 4 antibody detection tests in patients with neuromyelitis optica: a meta-analysis. Mult. Scler Relat. Disord. 2015;4(4):345–349. DOI: 10.1016/j.msard.2015.06.003Whittam D., Wilson M., Hamid S. et al. What's new in neuromyelitis optica? A short review for the clinical neurologist. J. Neurol. 2017;264(11):2330–2344. DOI: 10.1007/s00415-017-8445-8Waters P.J., Pittock S.J., Bennett J.L. et al. Evaluation of aquaporin-4 antibody assays. Clin. Exp. Neuroimmunol. 2014;5(3):290–303. DOI: 10.1111/cen3.12107Huda S., Whittam D., Bhojak M. et al. Neuromyelitis optica spectrum disorders. Clin. Med. (Lond). 2019;19(2):169–176. DOI: 10.7861/clinmedicine.19-2-169Palace J., Lin D.Y., Zeng D. et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain. 2019;142(5):1310–1323. DOI: 10.1093/brain/awz054Cиманив Т.О., Васильев А.В., Аскарова Л.Ш., Захарова М.Н. Оптиконейромиелит и заболевания спектра оптиконейромиелита. Журнал нев-рологии и психиатрии им. С.С. Корсакова. 2019;119(10-2):35–48.Краснов В.С., Тотолян Н.А., Назаров В.Д. и др. Актуальные вопросы диагностики заболеваний спектра оптиконейромиелита при определении антител к аквапорину-4 в сыворотке крови. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(7-2):24–31.Wingerchuk D.M., Lennon V.A., Lucchinetti C.F. et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805–815. DOI: 10.1016/S1474-4422(07)70216-8Contentti E.C., Rojas J.I., Cristiano E. et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult. Scler. Relat. Disord. 2020;45:102428. DOI: 10.1016/j.msard.2020.102428Симанив Т.О., Краснов В.С., Касаткин Д.С. Оптиконевромиелит в фокусе. Практическое руководство в схемах и таблицах. М.; 2023. 176 c.Jarius S., Aktas O., Ayzenberg I. et al. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) — revised re- commendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J. Neurol. 2023;270(7):3341–3368. DOI: 10.1007/s00415-023-11634-0Li R., Lu D., Li H. et al. Neuromyelitis optica spectrum disorders with non opticospinal manifestations as initial symptoms: a long-term observational study. BMC Neurol. 2021;21(1):35. DOI: 10.1186/s12883-021-02059-1Chitnis T., Ness J., Krupp L. et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology. 2016;86(3):245–252. DOI: 10.1212/WNL.0000000000002283Tenembaum S., Yeh E.A; Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC). Pediatric NMOSD: a review and position statement on approach to work-up and diagnosis. Front. Pediatr. 2020;8:339. DOI: 10.3389/fped.2020.00339Absoud M., Lim M.J., Appleton R. et al. Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features. J. Neurol. Neurosurg. Psychiatry. 2015;86(4):470–472. DOI: 10.1136/jnnp-2014-308550Baumann M., Sahin K., Lechner C. et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J. Neurol. Neurosurg. Psychiatry. 2015;86(3):265–272. DOI: 10.1136/jnnp-2014-308346Lechner C., Baumann M., Hennes E.M. et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J. Neurol. Neurosurg. Psychiatry. 2016;87(8):897–905. DOI: 10.1136/jnnp-2015-311743Kim H.J., Paul F., Lana-Peixoto M.A. et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84(11):1165–1173. DOI: 10.1212/WNL.0000000000001367Tenembaum S., Chitnis T., Nakashima I. et al. Neuromyelitis optica spectrum disorders in children and adolescents. Neurology. 2016;87(9 Suppl.2):S59–S66. DOI: 10.1212/WNL.0000000000002824Rostásy K., Mader S., Hennes E.M. et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult. Scler. 2013;19(8):1052–1059. DOI: 10.1177/1352458512470310Rice D.R., Nishiyama S., Pardo S. et al. A point-of-care diagnostic test for aquaporin-4 antibody seropositive neuromyelitis optica. Mult. Scler. Relat. Disord. 2022;60:103716. DOI: 10.1016/j.msard.2022.103716Majed M., Sanchez C.V., Bennett J.L. et al. Alterations in aquaporin-4-IgG serostatus in 986 patients: a laboratory-based longitudinal analysis. Ann. Neurol. 2023;94(4):727–735. DOI: 10.1002/ana.26722Chen X., Zhou J., Li R. et al. Disease course and outcomes in patients with the limited form of neuromyelitis optica spectrum disorders and negative AQP4-IgG serology at disease onset: a prospective cohort study. J. Clin. Neurol. 2022;18(4):453–462. DOI: 10.3988/jcn.2022.18.4.453Xue Q., Cao S., Rui Q. Reflections from a NMOSD case with serum AQP4-Ab negativity but CSF positivity: narrative review of how to interpret AQP4-Ab test results. Ann. Transl. Med. 2023;11(7):286. DOI: 10.21037/atm-20-4110Ross G.M.S., Filippini D., Nielen M.W.F., Salentijn G.I. Unraveling the hook effect: a comprehensive study of high antigen concentration effects in sandwich lateral flow immunoassays. Anal. Chem. 2020;92(23):15587–15595. DOI: 10.1021/acs.analchem.0c03740Van Beek N., Rentzsch K., Probst C. et al. Serological diagnosis of auto- immune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet. J. Rare Dis. 2012;7:49. DOI: 10.1186/1750-1172-7-49Robertson D., Savage K., Reis-Filho J.S., Isacke C.M. Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol. 2008;9:13. DOI: 10.1186/1471-2121-9-13Kitley J., Leite M.I., Nakashima I. et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135(Pt 6):1834–1849. DOI: 10.1093/brain/aws109Barć K., Gospodarczyk-Szot K., Nojszewska M. et al. The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: a visual evoked potential study. Mult. Scler. Relat. Disord. 2020;44:102265. DOI: 10.1016/j.msard.2020.102265Weinshenker B.G., Wingerchuk D.M., Vukusic S. et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann. Neurol. 2006;59(3):566–569. DOI: 10.1002/ana.20770Chan K.H., Lee C.Y. Treatment of neuromyelitis optica spectrum disorders. Int. J. Mol. Sci. 2021;22(16):8638. DOI: 10.3390/ijms22168638